scholarly journals Epidemiology of COVID-19 in Misrata, Libya: A Population-Based Surveillance Study

2021 ◽  
Vol 11 (01) ◽  
pp. 101-112
Author(s):  
Anas Zarmouh ◽  
Hussien Elaswdi ◽  
Essam Elakhtel ◽  
Khalid Abufalgha ◽  
Mohamed Taraina
Keyword(s):  
Population Based ◽  
Surveillance Study

Incidence of paediatric 10-fold medication errors in Wales

2020 ◽  
pp. archdischild-2020-319130
Author(s):  
Yincent Tse ◽  
David Tuthill
Keyword(s):  
Medication Errors ◽  
Reporting System ◽  
Patient Characteristics ◽  
Population Based ◽  
Population Surveillance ◽  
Near Miss ◽  
Surveillance Study ◽  
High Resource ◽  
Improvement Strategies ◽  
Iatrogenic Harm

ObjectivesTo estimate the incidence, characteristics and outcomes of 10-fold or greater or a tenth or less medication errors in children aged <16 years in Wales.DesignPopulation-based surveillance study July 2017 to June 2019. Cases were identified by paediatricians and hospital pharmacists using monthly electronic Welsh Paediatric Surveillance Unit (WPSU) reporting system.Patients‘Definite’ incident occurred when children received all or any of the incorrect dose of medication. ‘Near miss’ was where the prescribed, prepared or dispensed medication was not administered to the child.Main outcome measuresIncidence, patient characteristics, setting, drug characteristics, outcome, harm and enabling or preventive factors.ResultsIn total, 50 10-fold errors were reported; 20 definite and 30 near miss cases. This yields a minimum annual incidence of 1 per 3797 admissions, or 4.6/100 000 children. Of these, 43 were overdoses and 7 underdoses. 33 incidents occurred in children <5 years of age. Overall, 37 different medications were involved with the majority, 31 cases, being administered enterally. Of these 31 enteral medication errors, all definite cases (10) had received liquid preparations. Temporary harm occurred in 5/20 (25%) definite cases with one requiring intensive care; all fully recovered.ConclusionsIn this first ever population surveillance study in a high-resource healthcare system, 10-fold errors in children were rare, sometimes prevented and uncommonly caused harm. We recommend country-wide improvements be made to reduce iatrogenic harm. Understanding the enabling and preventive factors may help national improvement strategies to reduce these errors.

A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study

2019 ◽  
Vol 19 (2) ◽  
pp. 177-184 ◽  
Author(s):  
Darren W Westphal ◽  
Ashley Eastwood ◽  
Avram Levy ◽  
Jane Davies ◽  
Clare Huppatz ◽  
...  
Keyword(s):  
Western Australia ◽  
Vaccine Coverage ◽  
Population Based ◽  
Surveillance Study

scholarly journals Have we left some behind? Trends in socio-economic inequalities in breastfeeding initiation: A population-based epidemiological surveillance study

2014 ◽  
Vol 105 (5) ◽  
pp. e362-e368 ◽  
Author(s):  
Nathan C. Nickel ◽  
◽  
Patricia J. Martens ◽  
Dan Chateau ◽  
Marni D. Brownell ◽  
...  
Keyword(s):  
Population Based ◽  
Surveillance Study ◽  
Epidemiological Surveillance ◽  
Breastfeeding Initiation ◽  
Economic Inequalities

scholarly journals Duration of ruptured membranes and mother-to-child HIV transmission: a prospective population-based surveillance study

2015 ◽  
Vol 123 (6) ◽  
pp. 975-981 ◽  
Author(s):  
H Peters ◽  
L Byrne ◽  
A De Ruiter ◽  
K Francis ◽  
K Harding ◽  
...  
Keyword(s):  
Hiv Transmission ◽  
Population Based ◽  
Surveillance Study ◽  
Mother To Child

scholarly journals Timing of Identification Among Children With an Autism Spectrum Disorder: Findings From a Population-Based Surveillance Study

2009 ◽  
Vol 48 (5) ◽  
pp. 474-483 ◽  
Author(s):  
Paul T. Shattuck ◽  
Maureen Durkin ◽  
Matthew Maenner ◽  
Craig Newschaffer ◽  
David S. Mandell ◽  
...  
Keyword(s):  
Autism Spectrum Disorder ◽  
Population Based ◽  
Autism Spectrum ◽  
Spectrum Disorder ◽  
Surveillance Study

scholarly journals Population-Based Surveillance for HypermucoviscosityKlebsiella pneumoniaeCausing Community-Acquired Bacteremia in Calgary, Alberta

2013 ◽  
Vol 24 (3) ◽  
pp. e61-e64 ◽  
Author(s):  
Gisele Peirano ◽  
Johann DD Pitout ◽  
Kevin B Laupland ◽  
Bonnie Meatherall ◽  
Daniel B Gregson
Keyword(s):  
Klebsiella Pneumoniae ◽  
Clinical Presentation ◽  
Population Based ◽  
Surveillance Study ◽  
Liver Abscesses ◽  
Common Clinical Presentation

The characteristics of hypermucoviscosity isolates amongKlebsiella pneumoniaecausing community-acquired bacteremia were investigated. The hypermucoviscous phenotype was present in 8.2% ofK pneumoniaeisolates, and was associated with rmpA and the K2 serotype; liver abscesses were the most common clinical presentation. The present analysis represents the first population-based surveillance study of hypermucoviscosity amongK pneumoniaecausing bacteremia.

scholarly journals Family history and stroke outcome in a bi-ethnic, population-based stroke surveillance study

BMC Neurology ◽  
2005 ◽  
Vol 5 (1) ◽  
Author(s):  
Lynda D Lisabeth ◽  
Melinda A Smith ◽  
Devin L Brown ◽  
Ken Uchino ◽  
Lewis B Morgenstern
Keyword(s):  
Family History ◽  
Population Based ◽  
Surveillance Study ◽  
Stroke Outcome ◽  
Ethnic Population

scholarly journals OCCURRENCE OF SHIGELLOSIS IN THE YOUNG AND ELDERLY IN RURAL CHINA: RESULTS OF A 12-MONTH POPULATION-BASED SURVEILLANCE STUDY

2005 ◽  
Vol 73 (2) ◽  
pp. 416-422 ◽  
Author(s):  
XUAN-YI WANG ◽  
JI-CHAO CHEN ◽  
HYE-JON LEE ◽  
JING-CHEN MA ◽  
ZHAN-CHUN XING ◽  
...  
Keyword(s):  
Rural China ◽  
Population Based ◽  
Surveillance Study

scholarly journals 756. Clostridioides difficile Burden of Disease: A Prospective Population-Based Surveillance Study of Hospitalized Adults in Louisville, Kentucky

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S475-S476
Author(s):  
Stephen Furmanek ◽  
Ruth Carrico ◽  
Fredrick J Angulo ◽  
Joann Zamparo ◽  
Elisa Gonzalez ◽  
...  
Keyword(s):  
Laboratory Testing ◽  
Eligible Patient ◽  
The United States ◽  
Population Based ◽  
Surveillance Study ◽  
Clostridioides Difficile ◽  
Stool Samples ◽  
Stool Specimens ◽  
New Onset ◽  
Research Grant

Abstract Background Clostridioides difficile (C. difficile) is an important cause of morbidity and mortality. C. difficile infection (CDI) may be frequently under-diagnosed because laboratory confirmation requires collection of a stool specimen from a patient with diarrhea and appropriate laboratory testing. Methods A prospective population-based CDI surveillance study was launched in 8 adult hospitals in Louisville, Kentucky on September 16, 2019. Surveillance officers in each hospital identified all cases of new-onset diarrhea (≥3 loose stools in the past but not preceding 24 hours) in Louisville residents ≥50 years of age. After informed consent, stool samples were collected and tested at the University of Louisville reference laboratory for 1) glutamate dehydrogenase (GDH) and 2) Clostridioides difficile toxins A and B using C. DIFF QUIK CHEK COMPLETE®, Techlab. We defined CDI as GDH positive and toxin positive. The study was paused on April 3, 2020, due to COVID-19 restrictions. Results There were 85,719 eligible patient-days during the study period. A total of 1541 patients had new-onset diarrhea corresponding to 1.8 cases of new-onset diarrhea per 100 eligible patient-days. We enrolled 84% (1291/1541) of patients with new-onset diarrhea and tested stool samples for C. difficile from 82% (1055/1291) for a testing density of 123 per 10,000 patient-days. Of the 1055 tested stool specimens, 73 (7%) were GDH positive and toxin positive (Figure 1) yielding a hospital-based CDI incidence of 8.5 CDI cases per 10,000 patient-days. Figure 1. Patient Ascertainment Flow Chart Conclusion New-onset diarrhea was common among hospitalized adults ≥50 years of age. CDI was frequently identified through stool specimens collected from eligible inpatients with new-onset diarrhea. Further analysis of these data and additional laboratory testing will contribute to a better understanding of the frequency of CDI underdiagnosis and the burden of CDI in the United States. Disclosures Ruth Carrico, PhD, DNP, APR, CIC, Pfizer (Consultant, Research Grant or Support, Speaker's Bureau)Sanofi Pasteur (Consultant, Grant/Research Support, Speaker's Bureau) Fredrick J. Angulo, DVM, PhD, Pfizer, Inc. (Employee) Joann Zamparo, MPH, Pfizer, Inc. (Employee) Elisa Gonzalez, MS, Pfizer, Inc. (Employee) Kimbal D. Ford, PharmD, Pfizer, Inc. (Employee) Julio Ramirez, M.D., FACP, Pfizer, Inc. (Scientific Research Study Investigator, Research Grant or Support, Speaker's Bureau)

Sign in / Sign up

Export Citation Format

Share Document